- Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
- Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
- Ionis to host 2024 virtual Annual Meeting of Stockholders
- Ionis reports first quarter 2024 financial results
- Ionis Publishes 2023 Corporate Responsibility Report
- Ionis to hold first quarter 2024 financial results webcast
- Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
- Ionis to present at upcoming investor conferences
- Ionis to hold olezarsen Phase 3 data webcast
- Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
More ▼
Key statistics
On Wednesday, Ionis Pharmaceuticals Inc (IONS:NSQ) closed at 38.00, 3.94% above its 52-week low of 36.56, set on May 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 37.35 |
---|---|
High | 38.07 |
Low | 36.84 |
Bid | 37.50 |
Offer | 41.00 |
Previous close | 37.37 |
Average volume | 1.46m |
---|---|
Shares outstanding | 145.97m |
Free float | 144.70m |
P/E (TTM) | -- |
Market cap | 5.45bn USD |
EPS (TTM) | -2.67 USD |
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼